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license (http://creativeknown to be rate limiting for synapse formation. Studies have shown that administering specific nu-
trients may improve memory function, possibly by increasing synapse formation. This Dutch study
explores the Effect of a specific Nutritional Intervention on cerebral Glucose Metabolism in early
Alzheimer’s disease (NL-ENIGMA, Dutch Trial Register NTR4718, http://www.trialregister.nl/
trialreg/admin/rctview.asp?TC54718). The NL-ENIGMA study is designed to test whether the spe-
cific multinutrient combination Fortasyn Connect present in the medical food Souvenaid influences
cerebral glucose metabolism as a marker for improved synapse function.
Methods: This study is a double-blind, randomized controlled parallel-group single-center trial.
Forty drug-naive patients with mild cognitive impairment or mild dementia with evidence of amyloid
deposition are 1:1 randomized to receive either the multinutrient combination or placebo once daily.
Main exploratory outcome parameters include absolute quantitative positron emission tomography
with 18F-fluorodeoxyglucose (including arterial sampling) and standard uptake value ratios normal-
ized for the cerebellum or pons after 24 weeks.
Discussion: We expect the NL-ENIGMA study to provide further insight in the potential of this mul-
tinutrient combination to improve synapse function.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Nutritional intervention; Diet; Randomized clinical trial; Synapse formation; Synaptic activ-ity; [18F]FDG-PET1. Introduction
The complex pathophysiology of Alzheimer’s disease
(AD) has not yet been unravelled. Pathological changesthor. Tel.: 131 20 4448523; Fax: 131 20 4448529.
scheltens@vumc.nl
16/j.trci.2016.07.004
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).associated with cognitive decline, hallmarking this progres-
sive neurodegenerative disease, include accumulation of am-
yloid-b (Ab) plaques and neurofibrillary tangles. Synaptic
loss is already seen before these events occur, associated
with degeneration of the synaptic membrane leading to
reduced synaptic activity [1]. To date, there is no satisfactory
treatment for AD. Current pharmaceutical treatments, such
as acetylcholinesterase inhibitors donepezil, rivastigmine,imer’s Association. This is an open access article under the CC BY-NC-ND
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antagonist memantine, only provide a temporary reduction
of symptoms and are not without side effects, illustrating
the strong unmet need for effective therapeutic interventions
with fewer side effects.
Specific dietary intake, particularly the Mediterranean
diet, has been shown to be associated with a reduced risk
of cognitive decline and developing AD [2–11]. Based on
observations that the protective effects of diet cannot easily
be attributed to the actions of individual nutrients and that
the simultaneous enrichment of specific nutrients can act
synergistically in simulating membrane phospholipid
synthesis and increasing dendritic spine density,
Souvenaid—containing the multinutrient combination
Fortasyn Connect—has been developed to support synapse
formation and function in AD [12–14]. This multinutrient
combination comprises nutrients that act as precursors and
cofactors in the synthesis pathway of phosphatides, that is,
docosahexaenoic acid, eicosapentaenoic acid, uridine
monophosphate, choline, phospholipids, vitamins B6, B12,
C, and E, folate, and selenium. In AD patients, lower
plasma and brain levels of these nutrients have been
observed compared with controls [15]. In animal models,
including transgenic AD mice, dietary intervention with
this multinutrient combination has been shown to enhance
phospholipid synthesis, to maintain white and gray matter
integrity, to reduce the impact of amyloid-induced neurode-
generation and loss of functional connectivity, to increase
numbers of hippocampal cholinergic synapses, and to
improve cholinergic neurotransmission and hippocampus-
dependent cognitive performance [13,16–20].
Previous studies investigated the effect of Souvenaid in
patients with AD. Small but significant positive effects
have been observed on primary outcome memory function
in patients with mild AD in two separate randomized
controlled trials [21,22]. No effects were observed on
coprimary outcome Alzheimer’s Disease Assessment
Scale—Cognitive Subscale (ADAS-cog) [21]. In patients
with more advanced AD, who were on stable AD medica-
tion, no significant add-on effect of the multinutritional
intervention on primary outcome ADAS-cog was observed
[23]. Results of a large European Union–funded study in
prodromal AD patients are pending [24]. Probing the
mode of action of Souvenaid, a previous study in patients
with mild AD found effects on functional connectivity and
brain network organization based on secondary outcome
electroencephalography (EEG), suggesting that this multi-
nutrient combination affects synapse function [22,25].
Using magnetoencephalography (MEG) as exploratory
outcome parameter, this effect could not be replicated in a
smaller sample (Van Straaten et al., 2016, in preparation).
To further investigate the presumed effect of this multinu-
trient combination on synaptic function, we designed the
Dutch double-blind randomized controlled parallel-group
single-center study exploring the Effect of this specific
Nutritional Intervention on cerebral Glucose Metabolismin early Alzheimer’s disease (NL-ENIGMA, Dutch Trial
Register NTR4718, http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC54718). Synaptic function is as-
sessed using positron emission tomography with 18F-fluoro-
deoxyglucose ([18F]FDG-PET). [18F]FDG is a direct index
for synapse function and density because the uptake of
[18F]FDG is driven by synaptic terminals generating ATP
for synthesis, release, and recycling of neurotransmitters,
the maintenance of the normal resting potential, and the re-
covery from action potentials [26–28].
In the present study, the mode of action of the specific
multinutrient combination is further explored using struc-
tural magnetic resonance imaging (MRI), resting-state func-
tional MRI (rs-fMRI) networks, diffusion tensor imaging
(DTI), structural brain networks, derived using graph theory
based on DTI data, arterial spin labelling (ASL), and cere-
brospinal fluid (CSF) and blood markers. We hypothesize
that the intake of the multinutrient combination positively
affects glucose metabolism after 24-week intervention
compared with placebo.2. Methods and design
2.1. Patients
We include 40 patients from the VU University Alz-
heimer Center outpatient memory clinic diagnosed with
MCI or mild dementia because of AD (randomly distributed
based on availability). Diagnoses are made in a multidisci-
plinary consensus team, including at least a neurologist,
neuropsychologist, and neuroradiologist, and according to
the core clinical criteria of the National Institute on Aging
and Alzheimer’s Association [29–31]. For diagnosis of
MCI, impairment in one or more cognitive domains has to
be present, based on clinical interpretation of
performances on an extensive neuropsychological test
battery, whereas independency of functional abilities is
preserved [30]. Presence of AD pathology is evidenced by
the presence of abnormal AD biomarkers: CSF tau/Ab1–42
ratio . 0.52, positive [11C] Pittsburgh compound B (PiB),
or [18F]Florbetaben PET scan [32]. PET scans are visually
assessed by an experienced nuclear medicine physician
(BNMvB). [11C]PiB PET scans (w370MBq, 60–90minutes
post injection) are considered positive when abnormal bind-
ing is seen in more than one cortical brain region of interest
(ROI) (i.e., frontal, parietal, temporal, or occipital). [18F]
Florbetaben PET scans (w300 MBq, 90–110 minutes post
injection) are considered positive when abnormal binding
is seen in at least one cortical ROI (i.e., lateral temporal,
frontal, posterior cingulate, precuneus, and parietal). Further
inclusion criteria include 1) age between 50–85 (inclusive)
years old, 2) MMSE 20, and 3) availability of a study part-
ner. Exclusion criteria include 1) the presence of any other
significant neurological or psychiatric disorder; 2) diabetes;
3) stroke or severe white matter hyperintensities (defined as
Fazekas scale [33] score 3 on MRI); 4) use of donepezil,
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3 months before baseline; 5) contraindications to PET, arte-
rial sampling, or MRI; 6) use of omega-3 fatty acid–contain-
ing supplements or oily fish consumption more than twice a
week within 2 months before baseline; 7) use of atropine,
scopolamine, tolterodine, hyoscyamine, biperiden, benztro-
pine, trihexyphenidyl, oxybutynin, antipsychotics, vitamins
B, C, and/or E (.200% recommended daily intake), con-
sumption of high-energy and/or protein nutritional supple-
ments, a change in dose of lipid-lowering medication,
antidepressants, and antihypertensive medication, or the
use of other investigational products within 1 month before
baseline; and 8) investigator’s uncertainty regarding thewill-
ingness or ability of patient to comply with the protocol re-
quirements.
2.2. Randomization
Patients eligible for inclusion are 1:1 randomized to
receive the active product or the placebo product. To enable
equal distribution of the active product over different stages
of the disease, we stratify randomization based on MMSE
score at screening (group 1: MMSE 20–24, group 2:
MMSE 25–30). The details of the randomization are un-
known to the investigators, site staff, and study staff from
Nutricia Research.
2.3. Study product
The active product contains the specific multinutrient
combination Fortasyn Connect (for the nutritional composi-
tion, see Table 1). The placebo product is an isocaloric con-
trol drink lacking the specific multinutrient combination, but
otherwise identical to the active product. Participants
consume the products (125 mL) once daily at breakfast for
a period of 24 weeks. To check product compliance, we
ask participants and study partners to keep a diary for daily
registration of product adherence. We check compliance
with participant and partner at every visit and telephone
call (Fig. 1).Table 1
Nutritional composition of Fortasyn Connect
Component Amount per daily dose*
Eicosapentaenoic acid 300 mg
Docosahexaenoic acid 1200 mg
Phospholipids 106 mg
Choline 400 mg
Uridine monophosphate 625 mg
Vitamin E 40 mg
Selenium 60 mg
Vitamin B12 3 mg
Vitamin B6 1 mg
Folic acid 400 mg
Vitamin C 80 mg
*One bottle (125 mL) a day.2.4. Procedures
Patients eligible for participation are provided with oral
and written study information and at least a week for consid-
eration. When interested in participation, participant and
partner providewritten informed consent at start of first visit.
Screening and baseline visit are scheduled on the same day
or with a maximum interval of 4 weeks. At baseline visit
and after 24 weeks intervention, we collect all study param-
eters. During intervention period, three contact moments are
scheduled to check product compliance, adverse events, and
changes in medication use. A schematic diagram of the study
design is presented at Fig. 1.Wemaintain a window for visits
and phone calls of 67 days. Also, we attempt to schedule
baseline and follow-up MRI and PET scans on the same
time of the day to limit influences of the circadian rhythm
on outcome parameters (between and within patients).
During intervention, we request patients 1) not to use any
of the products mentioned in the exclusion criteria; 2) not to
change in dose or type of lipid lowering medication, antide-
pressants, and/or antihypertensive medication; and 3) not to
use (unless strictly necessary) sedative hypnotics and/or an-
xiolytics within 3 days before study visit.2.5. Main exploratory outcome parameters
Main objectives include exploring the effect of 24-week
intervention with active product on cerebral glucose meta-
bolism, assessed with [18F]FDG-PET imaging using quanti-
fication of regional cerebral metabolism rate for glucose, in
patients with MCI or mild dementia because of AD by
1. Absolute quantitative values using arterial sampling
and kinetic analysis and
2. Relative semiquantitative standardized uptake value
ratios (SUVr) with normalization regions (cerebellum
and pons) within a predefined standard uptake time in-
terval of 45–60 minutes post injection.2.6. Additional exploratory outcome parameters
Additionally, we explore the effect of 24-week interven-
tion with active product on the following:
1. Cerebral glucose metabolism as assessed with [18F]
FDG-PET imaging using quantification of [18F]Fig. 1. Schedule diagram of study design.
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latter using normalization regions (cerebellum and
pons), within different uptake time intervals post in-
jection;
2. MRI measurements including a) atrophy, b) mean syn-
chronization likelihood of the whole brain, c) mean
fractional anisotropy of voxels in white matter skel-
eton, d) structural brain networks, e) mean cerebral
blood flow in ADROIs, and f) volume of arterial blood
flow to the brain;
3. Blood markers, including vitamin E, homocysteine,
fatty acid profile in erythrocytes, and possible other
nutritional markers (to be determined later);
4. CSF markers, including Ab1–42, Ab1–40, total tau, tau
phosphorylated at threonine-181 (ptau), and possible
markers including nutritional parameters (to be deter-
mined later);
5. Cognitive tests assessing memory, attention, and exec-
utive functioning; and
6. Intake adherence, tolerance, and safety, including ex-
amination of patient medical history, recording of
adverse events, and monitoring of vital signs and addi-
tional laboratory parameters.2.7. Demographic and other baseline variables
At baseline, demographic information, that is, age, sex,
ethnicity, educational attainment (using the system of Ve-
rhage [34], ranging from 1 [low] to 7 [high]), fish consump-
tion, physical activity, smoking habits, alcohol consumption,
family history of AD, date of diagnosis MCI or dementia,
body height, and apolipoprotein (APOE) genotype, is
collected. For APOE genotyping, DNA is isolated from
10 mL blood samples, collected in EDTA tubes. APOE ge-
notype is determined using Light Cycler APOE mutation
detection method (Roche Diagnostics GmbH, Mannheim,
Germany).
2.8. PET assessment and analyses
A 60-minute dynamic [18F]FDG-PET scan (21 frames) is
performed on a Philips TF PET-CT scanner. Patients are in
fasting state for at least 8 hours. PET scan is preceded by
the placement of an arterial cannula in one of the radial ar-
teries. PET scan starts with a low-dose CT scan for attenua-
tion correction of PET data, and the administration of
approximately 180 MBq of [18F]FDG, dissolved in 5 mL
of saline.
2.8.1. Quantitative values
Together with tracer administration, dynamic scanning
and arterial blood sampling start. Arterial blood is with-
drawn continuously at a rate of 5 mL/minute for the first
5 minutes and 2.5 mL/minute thereafter until 60 minutes af-
ter injection. At set times (5, 10, 20, 40 and 60 minutes),
continuous withdrawal is interrupted briefly for the collec-tion of manual blood samples (5 mL), used to estimate
plasma-to-whole-blood ratios of radioactivity.
The whole-blood radioactivity concentration is continu-
ously measured in a well counter, cross-calibrated against
the PET scanner. Then, the plasma input function is derived
by multiplying the measured whole-blood curve with the
average plasma-to-blood ratios obtained from the discrete
samples.
2.8.2. Semiquantitative values
Semiquantitative SUV and SUVr are measured using
different uptake time windows after injection. SUVr are
normalized to cerebellar gray matter and whole pons uptake
values.
2.8.3. Region-of-interest analysis
Wewill define AD ROIs based on the MetaROI approach
described by Landau et al. [35]. Furthermore, we will
perform voxel-based analyses using statistical parametric
mapping. [18F]FDG influx rate constants (Ki) for the whole
brain are calculated with graphical analysis according to
the Patlak method [36]. As an input function, we use plasma
radioactivity concentration determined by arterial blood
sampling. Because net [18F]FDG uptake, described by Ki,
is directly proportional to glucose metabolic rate by multi-
plication with the plasma glucose concentration, the Ki re-
sults of the present study are valid for glucose metabolic
rates.
2.8.4. Parametric image analysis
Ki images are calculated using the Patlak method, again
for each combination of acquisition and reconstruction
methods, and with blood-sampling data as the input function
[36].2.9. MRI assessment and analyses
MRI is performed on a 3-T whole-body MR system
(Signa HDxt; GE medical Systems, Milwaukee, WI, USA)
using an eight-channel head coil. Structural images include
a sagittal 3D T1-weighted sequence for measuring atrophy
rates in different brain regions using voxel-based morphom-
etry. Mean synchronization likelihood of the brain is as-
sessed using rs-fMRI. Mean fractional anisotropy of
voxels in the white matter skeleton is assessed using DTI.
Structural brain networks based on DTI data are derived us-
ing graph theory. Mean cerebral blood flow in AD ROIs is
assessed using ASL, and volume of arterial blood flow to
the brain (measured mean blood flow in the carotid arteries
and basilar artery times the arterial lumen sizes) is assessed
using q-flow.2.10. Blood sampling and analyses
Venous blood is collected in fasting state. For future anal-
ysis, 12 mL clotted blood for serum and 18 mL EDTA blood
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stored at 280C according to the international standards
[37]. For safety monitoring, 4 mL EDTA blood and 3 mL
heparinized blood are collected and routinely analyzed.
2.11. CSF biomarkers
A total of 12.5 mL CSF is collected in two polypropylene
tubes via a lumbar puncture in intervertebral space at level
L3/L4, L4/L5, or L5/S1. Part of the CSF is used for routine
analyses including number of leucocytes, total protein, and
glucose. Within 2 h after collection, the rest is stored at
220C for analysis of Ab1–42, total tau, and ptau within 2
months using sandwich enzyme-linked immunosorbent as-
says (Innotest b-Amyloid1–42, Innotest hTAU-Ag, and Innot-
est Phosphotau(181P); Innogenetics, Gent, Belgium). The
remainder of the CSF is directly transferred to the Alzheimer
Center Biobank for storage and future analysis (including
Ab1–40). CSF is aliquoted into 0.5 mL samples and stored
at 280C according to the standard protocols [37].
2.12. Cognitive assessment
Memory is assessed using the Dutch version of the Rey
Auditory Verbal Learning Test immediate and delayed recall
and recognition test [38]. Attention and executive func-
tioning are assessed using the Trail Making Test (TMT) A
and TMT-B, respectively [39].
2.13. Sample size and interim analysis
To the best of our knowledge, there are no other random-
ized controlled trials that have investigated the effect of the
active product using [18F]FDG-PET. Based on the previous
[18F]FDG-PET studies, we have chosen a sample size of
40 completers [40–47], assuming to be sufficient to have
80% power of detecting a difference between the groups
of at least 0.91 standard deviation (SD) in an outcome
parameter at a significance level of .05 in a two-sided t test.
A study-conduct independent statistician will conduct an
interim analysis after 20 patients completed the study to
evaluate the estimate used in the sample size calculation
(of a difference between the groups of at least 0.91 SD).
Interim analysis will be performed on the [18F]FDG-PET
outcome parameters, using partially unblinded data. An in-
dependent Data Monitoring Committee will make recom-
mendations based on the results of interim analyses. Only
upward adaptation of the sample size is allowed.
2.14. Statistical analyses
Statistical analyses will be conducted using linear regres-
sion analyses, comparing change in outcome measure be-
tween the active and the placebo group, adjusted for the
baseline value of the particular outcome and MMSE. Addi-
tionally, we will explore whether baseline MMSE modifies
the intervention effect. The main outcome parameters willbe explored based on per-protocol analyses. Additional
intention-to-treat analyses will be carried out.
The significance level for the analysis of outcome vari-
ables will be set at,.05 in a two-sided test. Several potential
covariates and possible intervention effect moderators were
defined: MMSE at screening, diagnosis of dementia, rele-
vant medical events, relevant medication, coexisting dis-
eases, all the demographic and other baseline variables,
and product compliance.2.15. Ethical and legal considerations
This study follows the Helsinki Declaration’s principles,
meaning that all patients sign a written informed consent
stating that participation is voluntary and that participation
can be withdrawn at any time. The Local Medical Ethics Re-
view Committee approved the study on February 12, 2015.3. Discussion
The NL-ENIGMA study aims to explore the effect of
Souvenaid on cerebral glucose metabolism in mild to very
mild patients with biomarker proven AD. The study is a
single-center randomized controlled trial with double-blind
24-week intervention of Souvenaid or placebo in 40 drug-
naive patients with MCI or mild dementia and presence of
amyloid burden. Main exploratory outcome parameters
include absolute quantitative [18F]FDG uptake and relative
semiquantitative SUVr within a predefined time window.
Additionally, [18F]FDG SUV and SUVr using different up-
take time intervals, MRI, CSF and blood markers, and cogni-
tive tests are explored. First participant was included in
March 2015. We hypothesize to observe a positive effect
of the nutritional intervention compared with control prod-
uct on cerebral [18F]FDG uptake in AD-specific regions.
We use an exploratory approach because the effect of the
specific multinutrient combination has never been assessed
using [18F]FDG-PET. Previous studies have indicated that
this nutritional intervention increases synaptic density, en-
hances cholinergic neurotransmission, and reduces the
impact of amyloid-induced neurodegeneration and loss of
functional connectivity [13,16–20]. A previous clinical
study in patients with mild AD using EEG demonstrated
an effect of the multinutrient combination on functional
connectivity and brain network organization, suggesting
that its mode of action includes alteration of synapse
function [22,25]. A subsequent MEG study failed to
replicate this finding, possibly because of lack of power
and imbalanced group characterization (Van Straaten et al.,
2016, in preparation).
[18F]FDG-PET is a well-known method to study synapse
function [26–28]. As main outcome parameters, we include
quantitative [18F]FDG values because the active product
could affect the reference region. Sample size and duration
of intervention are based on [18F]FDG outcome
parameters. Additionally, SUVr, several MRI sequences,
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Because our approach is mainly biological and mechanical,
we will primarily conduct per-protocol analyses.
In conclusion, the NL-ENIGMA study is a randomized
controlled trial exploring the effect of Souvenaid on brain
glucose metabolism as measurement for synapse function
in 40 patients with MCI or early dementia because of AD.Acknowledgments
The NL-ENIGMA study is a collaboration between the VU
University Medical Center (VUmc) and Nutricia Research.
VUmc is the sponsor and is responsible for all aspects of
the clinical study. Nutricia Research is supporting as fol-
lows:
 responsible for the production of the study products
and the distribution of the study products to VUmc,
 contributes in safety monitoring,
 contributes scientific expertise for the clinical study.
 study monitoring is the responsibility of VUmc, and
Nutricia Research will perform comonitoring, and
 VUmc investigators have access to the final dataset,
and Nutricia Research will provide additional statisti-
cal input.
Conflicts of interest: The NL-ENIGMA study is an
investigator-initiated study funded by the Netherlands Orga-
nization for Scientific Research (NWO) within the Food,
Cognition, and Behavior (FCB) initiative, project N057-
13-003. N.M.E. Scheltens and I. Kuyper are funded by
NWO (project nr 057-13-003). F. Barkhof serves/has served
on the advisory boards of Bayer-Schering Pharma, Sanofi-
Aventis, Biogen Idec, UCB, Merck-Serono, Novartis, and
Roche. He has been a speaker at symposia organized by
the Serono Symposia Foundation. For all his activities, he re-
ceives no personal compensation. C.E. Teunissen serves on
the advisory board of Fujirebio and Roche, received research
consumables from Euroimmun, IBL, Fujirebio, Invitrogen,
and Mesoscale Discovery, performed contract research for
IBL, Shire, Boehringer, Roche and Probiodrug, and also
received grants from the European Commission, the Dutch
Research Council (ZonMW), Association of Frontotemporal
Dementia/Alzheimer’s Drug Discovery Foundation, ISAO,
and the Alzheimer’s Drug Discovery Foundation. Dr. Teu-
nissen received research consumables from Euroimmun,
IBL, Fujirebio, Invitrogen, and Mesoscale Discovery and
performed contract research for IBL, Shire, Boehringer,
Roche, and Probiodrug. L.M. Broersen and M.M. Lansber-
gen are full-time employees of Nutricia Research. Ph. Schel-
tens is fully employed by VU University Medical Center,
Amsterdam, and has received grant support (for the institu-
tion) from GE Healthcare, Nutricia Research, Piramal, and
MERCK. In the past 2 years, he has received consultancy/
speaker fees (paid to the institution) from Probiodrug, EIP
Pharma, Piramal, and GE Healthcare. R. Boellaard, W.M.
van der Flier, and B.N.M. van Berckel report no conflicts
of interest.RESEARCH IN CONTEXT
1. Systematic review: We searched PubMed for publi-
cations regarding the effect of nutritional interven-
tions on synapse formation in Alzheimer’s disease
(AD).
2. Interpretation: Specific dietary intake, particularly
the Mediterranean diet, has been shown to be associ-
ated with a reduced risk of cognitive decline and
developing AD. Several nutrients (e.g., docosahexa-
enoic acid, eicosapentaenoid acid, uridine mono-
phosphate, choline, phospholipids, certain vitamins,
and selenium) together act as precursors and cofac-
tors in the synthesis pathway of phosphatides, essen-
tial in formation of synapses. Souvenaid contains the
specific combination of these nutrients. In humans,
positron emission tomography with 18F-fluporodeox-
yglucose ([18F]FDG-PET) is the best technique to
investigate synapse function but has not been used
yet in combination with Souvenaid.
3. Future directions: In the present Dutch study
exploring the Effect of a specific Nutritional Inter-
vention on cerebral Glucose Metabolism in early
Alzheimer’s disease (NL-ENIGMA), we hypothe-
size that the active product will have a positive effect
compared with the control product on cerebral [18F]
FDG uptake in AD-specific regions. We expect the
present study to provide further insight into the po-
tential of an intervention to target synaptic function
in AD.
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